Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Samuel D, Cutler"'
Autor:
Philipp Knopf, Manal O. Elnenaei, Mohamed Abou El Hassan, Julie Wagner, Shashi Gujar, Daniel Gaston, Barry E. Kennedy, Jeanette E. Boudreau, Clinton J. V. Campbell, Samuel D. Cutler, Andrea J. Thoni, Nicholas A. Forward, Darrell White, Marissa Goudie
Publikováno v:
The Journal of Molecular Diagnostics. 23:1699-1714
Multiple myeloma presents with numerous primary genomic lesions that broadly dichotomize cases into hyperdiploidy or IgH translocated. Clinically, these large alterations are assessed by fluorescence in situ hybridization (FISH) for risk stratificati
Autor:
Samuel D, Cutler, Philipp, Knopf, Clinton J V, Campbell, Andrea, Thoni, Mohamed, Abou El Hassan, Nicholas, Forward, Darrell, White, Julie, Wagner, Marissa, Goudie, Jeanette E, Boudreau, Barry E, Kennedy, Shashi, Gujar, Daniel, Gaston, Manal O, Elnenaei
Publikováno v:
The Journal of molecular diagnostics : JMD. 23(12)
Multiple myeloma presents with numerous primary genomic lesions that broadly dichotomize cases into hyperdiploidy or IgH translocated. Clinically, these large alterations are assessed by fluorescence in situ hybridization (FISH) for risk stratificati
Autor:
Philipp Knopf, Manal O. Elnenaei, Marissa Goudie, Andrea Thoni, Darrell White, Daniel Gaston, Nicholas Allen Forward, Samuel D. Cutler, Julie Wagner
Publikováno v:
Blood. 136:37-38
Introduction: Multiple Myeloma (MM) is the second most common hematological malignancy in North America. It is characterized by invasion of the bone marrow by malignant plasma cells. This malignancy presents with a broad range of primary genomic lesi
Autor:
Mohamed Abou El Hassan, Wenda L. Greer, Nicholas A. Forward, Clinton J. V. Campbell, Samuel D. Cutler, Philipp Knopf, Manal O. Elnenaei, Julie Wagner, Daniel Gaston, Darrell White, Keaton Sinclair, Stephen Couban, Marissa Goudie
Publikováno v:
Clinical genetics. 96(2)
Multiple myeloma (MM) is an incurable hematological malignancy that relies on cytogenetic determination of copy number abnormalities (CNAs) for prognosis and management. Low-depth whole genome sequencing (LD-WGS) is a cost-effective alternative to ta